Caris Life Sciences, Inc. Common Stock
Here’s whether Caris Life Sciences, Inc. Common Stock (CAI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.15% over 10 days); RSI 29 — oversold; weak 1-year return of -47.4%; 3-month momentum negative (-23.2%). Currently 63.5% off its 52-week high. Score: -7/7.
CAI is trading below its 200-day MA ($22.04) — a key warning sign the longer-term trend is under pressure. An RSI of 29.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -47.4% compares to +16.5% for SPY (trailed the market by 63.8%). The current 63.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.